Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amgen 3Q

Sales in the U.S. were flat at $2.9 billion in the quarter and sales included a $64 million unfavorable impact due to U.S. Health Care Reform.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen 3Q

3Q Revenues: $3.8 billion (+1%)

3Q Earnings: $1.2 billion (-11%)

YTD Revenues: $11.2 billion (+3%)

YTD Earnings: $3.6 billion (-2%)

Comments: Sales in the U.S. were flat at $2.9 billion in the quarter and sales included a $64 million unfavorable impact due to U.S. Health Care Reform. International sales were up 2% to $838 million. Foreign exchange rates negatively impacted sales in the quarter by $16 million. Worldwide sales of Aranesp were down 9% to $623 million due to a decrease in demand. Sales of Epogen were $653 million (-2%). Combined worldwide sales of Neulasta and Neupogen were $1.3 billion (+4%). Enbrel sales were $914 million (-1%). Sensipar sales were up 6% to $175 million. R&D expenses were up 12% in the quarter to $689 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters